SYK
Stryker Corporation
NYSE: SYK · HEALTHCARE · MEDICAL DEVICES
$307.94
-1.36% today
Updated 2026-06-15
Market cap
$112.44B
P/E ratio
33.91
P/S ratio
4.45x
EPS (TTM)
$8.65
Dividend yield
1.15%
52W range
$281 – $402
Volume
2.5M
WallStSmart proprietary scores
59
out of 100
Grade: C+
Hold
Investment rating
6.0
Growth
B6.5
Quality
B6.5
Profitability
B4.0
Valuation
C3/9
Piotroski F-Score
Weak
2.2
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$429.42
+39.45%
12-Month target
$253.71
-17.61%
Intrinsic (DCF)
$223.02
Margin of safety
-35.20%
8 Strong Buy14 Buy7 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $415.00M — positive
Risks
- Piotroski 3/9 — weak financial health
- 35.20% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $18.45B | $20.50B | $22.59B | $25.12B | $25.27B | $27.6B |
| Net income | $2.36B | $3.17B | $2.99B | $3.25B | $745.00M | — |
| EPS | — | — | — | — | $8.65 | $15.12 |
| Free cash flow | $2.04B | $3.14B | $3.49B | $4.28B | $415.00M | — |
| Profit margin | 12.78% | 15.44% | 13.25% | 12.92% | 13.20% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-01 | STILES, SPENCER S | Sale | 1,607 | — |
| 2026-05-28 | FLETCHER, ROBERT S | Sale | 2,809 | $306.56 |
| 2026-05-28 | FLETCHER, ROBERT S | Sale | 1,067 | $307.30 |
Peer comparison
Smart narrative
Stryker Corporation trades at $307.94. representing a P/E of 33.91x trailing earnings. Our Smart Value Score of 59/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 2.18, it sits in the grey zone. TTM revenue stands at $25.27B. with profit margins at 13.20%. Our DCF model estimates intrinsic value at $223.02.
Frequently asked questions
What is Stryker Corporation's stock price?
Stryker Corporation (SYK) trades at $307.94, on a P/E of 33.9x and a P/S of 4.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Stryker Corporation overvalued?
Stryker Corporation carries a Smart Value Score of 59/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $223.02 against the $307.94 price, so on cash flow terms the market is paying a premium for Stryker Corporation's growth. The Hold rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Stryker Corporation (SYK)?
The 12-month analyst consensus target is $429.42, about 39.4% above the current $307.94. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of SYK by 2030?
Our research-backed model puts the 2030 base case at $1,160.39, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Stryker Corporation (SYK)?
Our DCF model estimates intrinsic value at $223.02, a -35.2% margin of safety versus today's $307.94. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Stryker Corporation's revenue?
Stryker Corporation's trailing twelve-month revenue is $25.27B, and our model projects it reaching about $36.89B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Stryker Corporation's Altman Z-Score is 2.18, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio4.45x
ROE14.97%
Beta0.81
50D MA$318.94
200D MA$355.69
Shares out0.38B
Float0.35B
Short ratio—
Avg volume2.5M
Performance
1 week+0.00%
1 month-0.36%
3 months-12.21%
YTD-13.03%
1 year—
3 years—
5 years—